=>
Uploading C:\Program Files\Stnexp\Queries\10583805.str



chain nodes :
8 9 10 11 12 13 14 20 26
ring nodes :
1 2 3 4 5 6 15 16 17 18 19 21 22 23 24 25
chain bonds :
3-8 5-11 8-9 8-10 11-12 12-13 13-14 14-15 14-21 19-20 25-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-19 16-17 17-18 18-19 21-22 21-25 22-23
23-24 24-25
exact/norm bonds :
8-9 8-10 15-16 15-19 16-17 17-18 18-19 21-22 21-25 22-23 23-24 24-25

exact bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-11 11-12 12-13 13-14 14-15 14-21 19-20
25-26
isolated ring systems :
containing 1 : 15 : 21 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS
21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10583805-HCl.str



chain nodes :
1 2
chain bonds :
1-2
exact bonds :
1-2

Match level :
1:CLASS 2:CLASS

L3 STRUCTURE UPLOADED

=> d his

FILE 'REGISTRY' ENTERED AT 21:36:15 ON 15 AUG 2008
L1 STRUCTURE UPLOADED
L2 34 S L1 SSS FULL

```
L3              STRUCTURE UPLOADED
L4           12 S L3 SSS FULL SUB=L2

     FILE 'CAPLUS' ENTERED AT 21:38:32 ON 15 AUG 2008
L5           61 S L4
L6           20 S L5 AND SPN/RL
L7       987000 S (POLYMORPH OR "XRD" OR "X-RAY" OR "X RAY")
L8            1 S L5 AND L7
L9           20 S L6 OR L8
L10           3 S US200!-583805/APPS
L11           1 S L9 AND L10
L12          19 S L9 NOT L10

=> d l11 bib abs

√L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:1355587  CAPLUS  Full-text
DN   144:74891
TI   Novel stable polymorphic forms of tiagabine hydrochloride
IN   Natarajan, Muthukumaran; Patel, Nileshkumar Sureshbhai; Bhatt, Mehul
     Chandrakatbhai; Kilaru, Srinivasu; Thennati, Rajamannar
PA   Sun Pharmaceutical Industries Limited, India
SO   PCT Int. Appl., 20 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        √APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005122698        A2    20051229    WO 2004-IN447          20041224
     WO 2005122698        A3    20060615
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     IN 2003MU01210       A     20060616    IN 2003-MU1210         20031124
     US 20070066656       A1    20070322    US 2006-583805         20060622 <--
PRAI IN 2003-MU1210       A     20031124
     WO 2004-IN447        W     20041224
AB   Stable polymorphic forms III, IV and substantially amorphous forms of an
     anticonvulsant, tiagabine-HCl.  Thus, a monoacetonitrile solvate of tiagabine-
     HCl was prepared by the reaction of the drug hydrochloride with MeCN.  The
     solvate was characterized by x-ray diffraction.


=> d l12 tot bib abs hitstr

√L12  ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2008 ACS on STN
PA   √Cephalon, Inc., USA
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

PI	WO 2008021559	A2	20080221	WO 2007-US18413	20070817
	US 20080051435	A1	20080228	US 2007-893524	20070816
PRAI	US 2006-838661P	P	√20060818		
	US 2007-893524	A	20070816		

√L12 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

SO Zhongguo Yiyao Gongye Zazhi √ (2006), 37(2), 75-77

√L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

SO Zhongguo Xinyao Zazhi √ (2005), 14(10), 1184-1187

√L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

√AU Anon.

SO Research Disclosure √ (2006), 505(May), P480 (No. 505017)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RD 505017		20060510	RD 2006-505017	20060510
PRAI	RD 2006-505017		√20060510		

√L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

SO Chemical Research in Chinese Universities √ (2006), 22(3), 351-355

√L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

PA √Nektar Therapeutics, USA

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006062980	A2	20060615	WO 2005-US44133	20051207
	WO 2006062980	A3	20070208		
PRAI	US 2004-633953P	P	√20041207		
	US 2004-633991P	P	20041207		

√L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

SO √Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.

CODEN: CNXXEV

	PATENT NO.	KIND	√DATE	APPLICATION NO.	DATE
PI	CN 1651426	A	20050810	CN 2004-10089084	20041203
PRAI	CN 2004-10089084		20041203		

√L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

PA √Ranbaxy Laboratories Limited, India

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006013550	A2	20060209	WO 2005-IB52611	20050804
	WO 2006013550	A3	20060413		
	IN 2004DE01448	A	20060721	IN 2004-DE1448	20040804
	IN 2007DN01638	A	20070803	IN 2007-DN1638	20070228
PRAI	IN 2004-DE1448	A	20040804		
	WO 2005-IB52611	W	√20050804		

√L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

PA √Ranbaxy Laboratories Limited, India

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092886	A1	20051006	WO 2005-IB809	√20050329
	IN 2004DE00615	A	20060602	IN 2004-DE615	20040329
PRAI	IN 2004-DE615	A	20040329		

√L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

SO Chinese Chemical Letters √ (2005), 16(9), 1205-1208

√L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

SO √Faming Zhuanli Shenqing Gongkai Shuomingshu, No pp. given

	PATENT NO.	KIND	√DATE	APPLICATION NO.	DATE
PI	CN 1554654	A	20041215	CN 2003-10122778	20031224
	CN 1651430	A	20050810	CN 2004-10102052	20041215
PRAI	CN 2003-10122778	A	20031224		

√L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020099013	A1	20020725	US 2001-933708	20010822
	US 20040087483	A1	20040506	US 2002-136433	20020502
	US 7163918	B2	20070116		
	US 20040063628	A1	20040401	US 2002-156527	20020529
	US 7060708	B2	20060613		
	IN 2003KN00775	A	20050204	IN 2003-KN775	20030613
	US 20070232529	A1	20071004	US 2004-923088	20040823
	US 20060014697	A1	20060119	US 2005-89056	20050325
	US 20070060500	A1	20070315	US 2006-392878	20060330
	US 20080086016	A1	20080410	US 2007-745019	20070507
	AU 2007203485	A1	20070816	AU 2007-203485	20070726
PRAI	US 2000-247556P	P	20001114		

√AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or

more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

√L12 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034237	A1	20020502	WO 2001-US26142	20010822
	US 6716452	B1	20040406	US 2000-642820	20000822
	CA 2420590	A1	20020502	CA 2001-2420590	20010822
	AU 2001086599	A	20020506	AU 2001-86599	20010822
	EP 1311242	A1	20030521	EP 2001-966056	20010822
	JP 2004523480	T	20040805	JP 2002-537291	20010822
	AU 2001286599	B2	20070621	AU 2001-286599	20010822
	IN 2003KN00329	A	20041009	IN 2003-KN329	20030320
	IN 2007KN01482	A	20080801	IN 2007-KN1482	20070425
	US 20080086016	A1	20080410	US 2007-745019	20070507
	AU 2007203485	A1	20070816	AU 2007-203485	20070726
	KR 2008006024	A	20080115	KR 2007-730727	20071228
PRAI	US 2000-642820	A	20000822		

√AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

L12 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:13958 CAPLUS Full-text
DN 128:80001
OREF 128:15547a,15550a
TI Modified form of the tiagabine hydrochloride
IN Ahrndt, Preben; Petersen, Henning Borge; Chang, Vincent H.; Allen, Kimberly Ann; Chain, Michael H.
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9747619	A1	19971218	WO 1997-DK244	19970603
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2257931	A1	19971218	CA 1997-2257931	19970603
	CA 2257931	C	20061212		
	AU 9731653	A	19980107	AU 1997-31653	19970603
	AU 723267	B2	20000824		
	EP 906309	A1	19990407	EP 1997-927006	19970603
	EP 906309	B1	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1225094	A	19990804	CN 1997-196341	19970603

	BR 9709725	A	19990810	BR 1997-9725	19970603
	HU 9904035	A2	20000528	HU 1999-4035	19970603
	HU 9904035	A3	20000728		
	JP 2000511909	T	20000912	JP 1998-501077	19970603
	IL 127469	A	20010111	IL 1997-127469	19970603
	RU 2177478	C2	20011227	RU 1999-100703	19970603
	AT 223405	T	20020915	AT 1997-927006	19970603
	PT 906309	T	20021231	PT 1997-927006	19970603
	ES 2181002	T3	20030216	ES 1997-927006	19970603
	CN 1636565	A	20050713	CN 2004-10092623	19970603
	CZ 295578	B6	20050817	CZ 1998-4019	19970603
	PL 190858	B1	20060228	PL 1997-330424	19970603
	US 5958951	A	19990928	US 1997-872380	19970610
	IN 1997MA01240	A	20050304	IN 1997-MA1240	19970610
	ZA 9705266	A	19980204	ZA 1997-5266	19970613
	NO 9805809	A	19981211	NO 1998-5809	19981211
	NO 316889	B1	20040614		
	KR 2000016580	A	20000325	KR 1998-710175	19981211
PRAI	DK 1996-661	A	19960614		
	WO 1997-DK244	W	19970603		

AB R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid-HCl (tiagabine-HCl) in its pure and stable anhydrous form is described. Thus, tiagabine-HCl monohydrate (75 g) was dissolved in 613 mL water at 65°. The solution was filtered and 37 g concentrate HCl in 115 g water was added to the above solution, the while solution cooled and filtered and the precipitate was dried to give the anhydrous form of tiagabine_HCl.

√L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:154157 CAPLUS Full-text
DN 124:260795
OREF 124:48311a,48314a
TI The synthesis of novel GABA uptake inhibitors. II. Synthesis of 5-hydroxytiagabine, a human metabolite of the GABA reuptake inhibitor tiagabine. [√Erratum to document cited in CA121:205185]
AU Andersen, Knud E.; Begtrup, Mikael; Chorghade, Mukund S.; Lee, Elaine C.; Lau, Jesper; Lundt, Behrend F.; Petersen, Hans; Soerensen, Per O.; Thoegersen, Henning
CS Den.
SO Tetrahedron (1996), 52(10), 3375
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English
AB The errors were not reflected in the abstract or the index entries.

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1994:605185 CAPLUS Full-text
DN 121:205185
OREF 121:37357a,37360a
TI The synthesis of novel GABA uptake inhibitors. Part 2. Synthesis of 5-hydroxytiagabine, a human metabolite of the GABA reuptake inhibitor tiagabine
AU Andersen, Knud E.; Begtrup, Mikael; Chorghade, Mukund S.; Lee, Elaine C.; Lau, Jesper; Lundt, Behrend F.; Petersen, Hans; Soerensen, Per O.; Thoegersen, Henning
CS Novo Nordisk A/S, Nordisk Park, DK-2760, Den.
SO Tetrahedron (1994), 50(29), 8699-10

CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
GI



I

AB (R)-1-[4-(2,5-Dihydro-3-methyl-5-oxothien-2-ylidene)-4-(3-methyl-2-thienyl)butyl]-3-piperidinecarboxylic acid (5-hydroxytiagabine) (I) was prepared in 8 steps from 2-bromo-3-methylthiophene. Key steps are Grignard reactions, displacement of heteroarom. Cl with methoxy, and simultaneously demethylation and opening of a hydroxymethylcyclopropane with bromotrimethylsilane. A metalloporphyrin assisted hydroxylation of tiagabine also yielded the target metabolite. The structure of 5-hydroxytiagabine was confirmed by NMR-data including COSY, ROESY, HMQC and HMBC expts.
IT 145821-59-6, Tiagabine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxylation)
RN 145821-59-6 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:472468 CAPLUS Full-text
DN 119:72468
OREF 119:13057a,13060a
TI The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (Tiagabine) as an anticonvulsant drug candidate
AU Andersen, Knud Erik; Braestrup, Claus; Groenwald, Frederik C.; Joergensen,

Anker S.; Nielsen, Erik B.; Sonnewald, Ursula; Soerensen, Per O.; Suzdak, Peter D.; Knutsen, Lars J. S.

CS Pharm. Div., Novo Nordisk A/S, Maaloev, DK 2760, Den.

SO Journal of Medicinal Chemistry (1993), 36(12), 1716-25
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI



I



II

AB A series of different synthetic approaches to novel GABA uptake inhibitors are described, leading to examples which are derivs. of nipecotic acid and guvacine, substituted at nitrogen by 4,4-diaryl-3-butenyl or 2-(diphenylmethoxy)ethyl moieties. Thus, diaryl/heteroarylbutenylpiperidi nes I (R1 = Ph, substituted Ph, 3-methyl-2-thienyl, 1-methyl-2-pyrrolyl, R2 = Ph, substituted Ph, 2-thienyl, 3-methyl-2-thienyl) were prepared Bromobis(methylthienyl)butene II reacted with Et 3-piperidinecarboxylate to give an intermediate [bis(methylthienyl)butenyl]piperidinecarboxylate which was hydrolyzed to give I (R1 = R2 = 3-methyl-2-thienyl). The in vitro value for inhibition of [3H]-GABA uptake in rat synaptosomes was determined for each compound It was found that the most potent examples are those having a substituent in an "ortho" position in one or both aromatic/heteroarom. groups. The majority of the compds. described are structurally related to tiagabine, (R)-1-[4,4-bis(3-methyl-2-theinyl)-3- butenyl]-3-piperidinecarboxylic acid hydrochloride (NNC 05-0328) and some of the reasoning behind the selection of this compound as a drug candidate is summarized.

√L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN -checked xrd

AN 1993:80815 CAPLUS Full-text

DN 118:80815

OREF 118:14217a,14220a

TI Crystalline tiagabine hydrochloride monohydrate, a method for its preparation and use as antiepileptic

IN Petersen, Henning; Nielsen, Peter; Cain, Michael; Patel, R. Subhash

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9217473	A1	19921015	WO 1992-DK93	19920323
	W: AU, BG, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2107223	A1	19921003	CA 1992-2107223	19920323
	CA 2107223	C	20050215		
	AU 9216415	A	19921102	AU 1992-16415	19920323

	AU 661483	B2	19950727		
	EP 579681	A1	19940126	EP 1992-908325	19920323
	EP 579681	B1	19990602		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 06506209	T	19940714	JP 1992-507965	19920323
	JP 3001975	B2	20000124		
	AT 180781	T	19990615	AT 1992-908325	19920323
	ES 2134801	T3	19991016	ES 1992-908325	19920323
	US 5354760	A	19941011	US 1992-857038	19920324
	IL 101358	A	19960804	IL 1992-101358	19920324
	ZA 9202297	A	19921230	ZA 1992-2297	19920330
	FI 110096	B1	20021129	FI 1993-4298	19930930
	NO 9303524	A	19931001	NO 1993-3524	19931001
	NO 304113	B1	19981026		
PRAI	DK 1991-582	A	19910402		
	WO 1992-DK93	A	19920323		

AB Crystalline tiagabine hydrochloride monohydrate (I) is claimed. The use of I as antiepileptic agent is claimed (no data). Thus, Et tiagabinate was saponified and converted to the hydrochloride; this hydrochloride (174 g) was dissolved in water (5200 mL) and treated with concentrate HCl (154 mL) to give 99.7% pure I.

L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1987:515495 CAPLUS Full-text

DN 107:115495

OREF 107:18718h,18719a

TI Diheterocyclylbutenylamino acids as GABA uptake inhibitors

IN Groenvald, Frederik Christian; Braestrup, Claus

PA Novo Industri A/S, Den.

SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8700171	A1	19870115	WO 1986-DK76	19860626
	W: AU, DK, FI, JP, NO, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	ZA 8604608	A	19870225	ZA 1986-4608	19860620
	CA 1284503	C	19910528	CA 1986-512333	19860624
	AU 8661336	A	19870130	AU 1986-61336	19860626
	AU 599326	B2	19900719		
	EP 236342	A1	19870916	EP 1986-904114	19860626
	EP 236342	B1	19910911		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 62503172	T	19871217	JP 1986-503845	19860626
	JP 07103116	B	19951108		
	AT 67196	T	19910915	AT 1986-904114	19860626
	FI 8700810	A	19870225	FI 1987-810	19870225
	FI 89355	B	19930615		
	FI 89355	C	19930927		
	NO 8700781	A	19870225	NO 1987-781	19870225
	NO 168823	B	19911230		
	NO 168823	C	19920408		
	DK 8701008	A	19870226	DK 1987-1008	19870226
	DK 156398	B	19890814		
	DK 156398	C	19900108		
	US 5010090	A	19910423	US 1988-254557	19881007

PRAI DK 1985-2883 A 19850626
EP 1986-904114 A 19860626
WO 1986-DK76 A 19860626
US 1987-33084 B2 19870224
OS MARPAT 107:115495
GI



II



III

AB R1R2C:CHCH2CH2R3 [I; R1, R2 = (un)substituted furanyl, thienyl, pyridyl, pyrrolyl; R3 = 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyrid- 1-yl, 3-carboxymethylpyrrolidin-1-yl] and salts thereof were prepared as γ-aminobutyric acid uptake inhibitors. Cyclopropylmagnesium bromide reacted with di(2-thienyl) ketone to give di(2-thienyl)cyclopropyl carbinol, which reacted with HBr to give 4,4-di(2-thienyl)-3-butenyl bromide. This was aminated by Et nipecotate to give an intermediate which was saponified to afford dithienylbutenylnipecotic acid II. Dipyrrolylbutenylnipecotic acid III inhibited γ-aminobutyric acid uptake in Fjalland's screen with an IC50 of 60 nM. Capsules were prepared containing II 125, Mg stearate 2, and lactose 200 mg.

=> log hold

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 21:40:23 ON 15 AUG 2008